GlobeNewswire by notified

Transactions in connection with share buy-back program

Share

Company Announcement

COPENHAGEN, Denmark; March 27, 2023 –Genmab A/S (Nasdaq: GMAB). On February 22, 2023, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program.

The share buy-back program is expected to be completed no later than March 31, 2023, and comprises up to 220,000 shares.

The following transactions were executed under the program from March 20, 2023, to March 24, 2023:

No. of sharesAverage price (DKK)Total value (DKK)
Accumulated through last announcement167,000427,631,620
March 20, 20236,0002,504.2415,025,440
March 21, 20235,000 2,541.7712,708,850
March 22,20235,0002,541.4412,707,200
March 23, 20237,0002,529.9917,709,930
March 24, 20237,0002,564.9117,954,370
Total30,00076,105,790
Accumulated under the program197,000503,737,410

Details of each transaction are included as an appendix to this announcement.

Following these transactions, Genmab holds 740,416 shares as treasury shares, corresponding to 1.12% of the total share capital and voting rights.

The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Further details on the terms of the share buy-back program can be found in our company announcement no. 06 dated February 22, 2023.

About Genmab
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.

Contact:          
Marisol Peron, Senior Vice President, Global Communications and Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on
www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody® and HexElect®.

Company Announcement no. 16
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Placeringsf. Nykredit Invest (Kapitalforening) – estimerede udlodninger for 20238.12.2023 15:37:01 CET | pressemeddelelse

På baggrund af de skattepligtige indtægter for 2023 har Placeringsf. Nykredit Invest (Kapitalforening) nu estimeret følgende ureviderede udlodninger for foreningens afdelinger for 2023: AfdelingISINValutaUdbytte pr. andelDanske FokusaktierDK0060231777DKK12,90Kredit Fokus KLDK0061066842DKK0,00 Det bemærkes, at der alene er tale om estimerede udlodninger, hvorfor der vil kunne ske ændringer. Der gøres endvidere opmærksom på at fx handelsaktivitet mv. i den resterende del af året kan påvirke de estimerede udlodninger i såvel opadgående som nedadgående retning. Endelige estimerede udlodninger vil blive offentliggjort på Nasdaq Copenhagen A/S den 24. januar 2024 og forventes udbetalt til investorerne den 2. februar 2024. Eventuel henvendelse vedrørende denne meddelelse kan rettes til direktør Tage Fabrin-Brasted, tlf. 44 55 92 00. Med venlig hilsen Placeringsforeningen Nykredit Invest Tage Fabrin-Brasted, direktør Vedhæftet fil FB_Plac_NI_estimerede_udlodninger_8_12_2023

Investeringsforeningen Investin – estimerede udlodninger for 20238.12.2023 15:23:20 CET | pressemeddelelse

På baggrund af de skattepligtige indtægter for 2023 har Investeringsforeningen Investin nu estimeret følgende ureviderede udlodninger for foreningens afdelinger for 2023: AfdelingISINValutaUdbytte pr. andelEMD Local CurrencyDK0060542504DKK0,00Sampension Globale Aktier KLDK0061074861DKK3,10Sampension Obligationer KLDK0061076213DKK0,00I&T Nordiske Aktier Large CapDK0061276656DKK0,00I&T Globale Aktier ESG SelectDK0061276573DKK5,80 Det bemærkes, at der alene er tale om estimerede udlodninger, hvorfor der vil kunne ske ændringer. Der gøres endvidere opmærksom på at fx handelsaktivitet mv. i den resterende del af året kan påvirke de estimerede udlodninger i såvel opadgående som nedadgående retning. Endelige estimerede udlodninger vil blive offentliggjort på Nasdaq Copenhagen A/S den 16. januar 2024 og forventes udbetalt til investorerne den 25. januar 2024. Eventuel henvendelse vedrørende denne meddelelse kan rettes til direktør Tage Fabrin-Brasted, tlf. 44 55 92 00. Med venlig hilsen Invest

Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions8.12.2023 15:15:00 CET | Press release

With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefitand stability in secondary endpoints including overall survival (OS)1,2 iDFS benefit remains consistent across key patient subgroups; among patients with stage II and stage III tumors, Kisqali lowered risk by 30% and 24.5%, respectively1,2 Latest analysis continues to show a well-tolerated safety profile in line with previously reported results, and quality of life for Kisqali patients preserved vs. endocrine therapy (ET) alone1,2,3 Risk of recurrence remains a short and long term concern; one in eight women treated with ET alone in NATALEE likely to experience invasive disease at 3 years1,2 Kisqali is currently approved in the metastatic setting, where it has consistently demonstrated statistically significant OS benefit across three Phase III trials4-15;Novartis has filed NATALEE results with EMA and will subm